Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant

Takehito Mayumi, Kohei Nagasawa, Toyoshi Inoguchi, Yasuo Yamauchi, Yoshitomo Ishii, Yoshifumi Tada, Fumio Umeda, Yoshiyuki Niho

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    To elucidate the mechanism of vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant changes in factors associated with haemostasis were investigated. The lupus anticoagulant was associated with an increased incidence of thrombosis, particularly cerebral thrombosis. Concentrations of fibrinopeptide A and fibrinopeptide Bpi5-4 were significantly raised in the plasma of patients with systemic lupus erythematosus and the anticoagulant compared with concentrations in patients without the lupus anticoagulant. The tendency towards formation of thrombosis was not found in all lupus patients with the anticoagulant, however. Concentrations of thromboxane B2 were remarkably raised in the plasma of the two patients with the lupus anticoagulant who had recently had thrombosis. Concentrations of 6-keto-prostaglandin Fla, protein C, antithrombin mI, and plasminogen were similar in both groups. No significant decrease in serum stimulatory activity on prostacyclin production by cultured aortic endothelial cells was noted in lupus patients with the anticoagulant, but inhibition was present in the two patients with recent thrombosis. These results indicate that although patients with the lupus anticoagulant are not always in a hypercoagulable state, haemostatic abnormalities found in some patients with the anticoagulant may be predictive of thrombotic events.

    Original languageEnglish
    Pages (from-to)543-547
    Number of pages5
    JournalAnnals of the Rheumatic Diseases
    Volume50
    Issue number8
    DOIs
    Publication statusPublished - Jan 1 1991

    Fingerprint

    Lupus Coagulation Inhibitor
    Hemostatics
    Systemic Lupus Erythematosus
    Blood Vessels
    Thrombosis
    Anticoagulants
    Fibrinopeptide A
    Plasmas
    Thromboxane B2
    Antithrombins
    Plasminogen
    Endothelial cells
    Epoprostenol
    Protein C
    Prostaglandins
    Intracranial Thrombosis
    Hemostasis
    Endothelial Cells

    All Science Journal Classification (ASJC) codes

    • Immunology and Allergy
    • Rheumatology
    • Immunology
    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. / Mayumi, Takehito; Nagasawa, Kohei; Inoguchi, Toyoshi; Yamauchi, Yasuo; Ishii, Yoshitomo; Tada, Yoshifumi; Umeda, Fumio; Niho, Yoshiyuki.

    In: Annals of the Rheumatic Diseases, Vol. 50, No. 8, 01.01.1991, p. 543-547.

    Research output: Contribution to journalArticle

    Mayumi, Takehito ; Nagasawa, Kohei ; Inoguchi, Toyoshi ; Yamauchi, Yasuo ; Ishii, Yoshitomo ; Tada, Yoshifumi ; Umeda, Fumio ; Niho, Yoshiyuki. / Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. In: Annals of the Rheumatic Diseases. 1991 ; Vol. 50, No. 8. pp. 543-547.
    @article{47150d35ad3941a18bc2e753d990932e,
    title = "Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant",
    abstract = "To elucidate the mechanism of vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant changes in factors associated with haemostasis were investigated. The lupus anticoagulant was associated with an increased incidence of thrombosis, particularly cerebral thrombosis. Concentrations of fibrinopeptide A and fibrinopeptide Bpi5-4 were significantly raised in the plasma of patients with systemic lupus erythematosus and the anticoagulant compared with concentrations in patients without the lupus anticoagulant. The tendency towards formation of thrombosis was not found in all lupus patients with the anticoagulant, however. Concentrations of thromboxane B2 were remarkably raised in the plasma of the two patients with the lupus anticoagulant who had recently had thrombosis. Concentrations of 6-keto-prostaglandin Fla, protein C, antithrombin mI, and plasminogen were similar in both groups. No significant decrease in serum stimulatory activity on prostacyclin production by cultured aortic endothelial cells was noted in lupus patients with the anticoagulant, but inhibition was present in the two patients with recent thrombosis. These results indicate that although patients with the lupus anticoagulant are not always in a hypercoagulable state, haemostatic abnormalities found in some patients with the anticoagulant may be predictive of thrombotic events.",
    author = "Takehito Mayumi and Kohei Nagasawa and Toyoshi Inoguchi and Yasuo Yamauchi and Yoshitomo Ishii and Yoshifumi Tada and Fumio Umeda and Yoshiyuki Niho",
    year = "1991",
    month = "1",
    day = "1",
    doi = "10.1136/ard.50.8.543",
    language = "English",
    volume = "50",
    pages = "543--547",
    journal = "Annals of the Rheumatic Diseases",
    issn = "0003-4967",
    publisher = "BMJ Publishing Group",
    number = "8",

    }

    TY - JOUR

    T1 - Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant

    AU - Mayumi, Takehito

    AU - Nagasawa, Kohei

    AU - Inoguchi, Toyoshi

    AU - Yamauchi, Yasuo

    AU - Ishii, Yoshitomo

    AU - Tada, Yoshifumi

    AU - Umeda, Fumio

    AU - Niho, Yoshiyuki

    PY - 1991/1/1

    Y1 - 1991/1/1

    N2 - To elucidate the mechanism of vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant changes in factors associated with haemostasis were investigated. The lupus anticoagulant was associated with an increased incidence of thrombosis, particularly cerebral thrombosis. Concentrations of fibrinopeptide A and fibrinopeptide Bpi5-4 were significantly raised in the plasma of patients with systemic lupus erythematosus and the anticoagulant compared with concentrations in patients without the lupus anticoagulant. The tendency towards formation of thrombosis was not found in all lupus patients with the anticoagulant, however. Concentrations of thromboxane B2 were remarkably raised in the plasma of the two patients with the lupus anticoagulant who had recently had thrombosis. Concentrations of 6-keto-prostaglandin Fla, protein C, antithrombin mI, and plasminogen were similar in both groups. No significant decrease in serum stimulatory activity on prostacyclin production by cultured aortic endothelial cells was noted in lupus patients with the anticoagulant, but inhibition was present in the two patients with recent thrombosis. These results indicate that although patients with the lupus anticoagulant are not always in a hypercoagulable state, haemostatic abnormalities found in some patients with the anticoagulant may be predictive of thrombotic events.

    AB - To elucidate the mechanism of vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant changes in factors associated with haemostasis were investigated. The lupus anticoagulant was associated with an increased incidence of thrombosis, particularly cerebral thrombosis. Concentrations of fibrinopeptide A and fibrinopeptide Bpi5-4 were significantly raised in the plasma of patients with systemic lupus erythematosus and the anticoagulant compared with concentrations in patients without the lupus anticoagulant. The tendency towards formation of thrombosis was not found in all lupus patients with the anticoagulant, however. Concentrations of thromboxane B2 were remarkably raised in the plasma of the two patients with the lupus anticoagulant who had recently had thrombosis. Concentrations of 6-keto-prostaglandin Fla, protein C, antithrombin mI, and plasminogen were similar in both groups. No significant decrease in serum stimulatory activity on prostacyclin production by cultured aortic endothelial cells was noted in lupus patients with the anticoagulant, but inhibition was present in the two patients with recent thrombosis. These results indicate that although patients with the lupus anticoagulant are not always in a hypercoagulable state, haemostatic abnormalities found in some patients with the anticoagulant may be predictive of thrombotic events.

    UR - http://www.scopus.com/inward/record.url?scp=0025885372&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0025885372&partnerID=8YFLogxK

    U2 - 10.1136/ard.50.8.543

    DO - 10.1136/ard.50.8.543

    M3 - Article

    C2 - 1909517

    AN - SCOPUS:0025885372

    VL - 50

    SP - 543

    EP - 547

    JO - Annals of the Rheumatic Diseases

    JF - Annals of the Rheumatic Diseases

    SN - 0003-4967

    IS - 8

    ER -